Not available
Quote | Assembly Biosciences Inc. (NASDAQ:ASMB)
Last: | $13.48 |
---|---|
Change Percent: | -0.98% |
Open: | $13.4 |
Close: | $13.48 |
High: | $13.48 |
Low: | $13.05 |
Volume: | 5,632 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Assembly Biosciences Inc. (NASDAQ:ASMB)
2024-04-07 03:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-28 17:03:15 ET More on Assembly Biosciences Assembly Biosciences announces effective date of reverse stock split Seeking Alpha’s Quant Rating on Assembly Biosciences Historical earnings data for Assembly Biosciences Financial information for As...
Message Board Posts | Assembly Biosciences Inc. (NASDAQ:ASMB)
Subject | By | Source | When |
---|---|---|---|
ASBM abandons HBV arena, for all practical purposes: | DewDiligence | investorshub | 04/18/2023 5:57:44 PM |
ASBM 4Q22 results12/31/22 cash=$92M(down_from $109M @9/30/22): | DewDiligence | investorshub | 03/22/2023 9:18:31 PM |
ASMB halts development of ABI-H3733, an HBV core inhibitor: | DewDiligence | investorshub | 03/22/2023 9:17:28 PM |
ASMB(+14%)reports_interim phase1/1b data_for HBV core inhibitors: | DewDiligence | investorshub | 12/19/2022 2:52:01 PM |
whytestocks: $ASMB News Article - Assembly Biosciences Doses First Subject in Phase 1a Clinical Tria | whytestocks | investorshangout | 11/14/2022 6:10:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-04-07 03:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with rec...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...